The subpoena broadly requests documents regarding promotional, educational and other activities relating to Botox. The company’s current understanding is that the inquiry involves questions regarding alleged off label promotion relating to the use of Botox for the treatment of headache.
Allergan has said that it will fully cooperate with the US Department of Justice to satisfactorily address any and all of their questions regarding this matter.